case_images: PMC10294262_01
case_images: Timeline illustrating schedule of treatment and dosing with T-VEC.
case_images: cde530851_f01.jpg
case_images: PMC10294262_01_cde530851_f01.jpg
case_images: F1
case_images: The patient began intralesional T-VEC injections on September 23rd, 2020 (timeline shown in Fig. 1) and has continued to respond to treatment through her last follow-up visit on September 21st, 2022.
case_images: Clinical regression of CSCC in renal transplant patient after intralesional injection of T-VEC. a CSCC lesion on May 19th, 2021, before intratumoral injection of 1 mL T-VEC. b June 30th, 2021, 6 weeks after intratumoral T-VEC injection.
case_images: cde530851_f02.jpg
case_images: PMC10294262_01_cde530851_f02.jpg
case_images: F2
case_images: Complete regressions on some lesions were observed within 6 weeks of intralesional T-VEC injections (Fig. 2).
case_images: Histopathologic imaging of CSCC tumor following intralesional administration of T-VEC (hematoxylin-eosin, original magnification, x10).
case_images: cde530851_f03.jpg
case_images: PMC10294262_01_cde530851_f03.jpg
case_images: F3
case_images: Pathology from the resections showed no residual tumor and marked lymphocytic inflammation (Fig. 3).